Clinical trial · Interventional
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Stem Cell Transplant as Standard Therapy for Symptomatic Multiple Myeloma
NCT00004165CI-TRIAL-00007097completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase III trial to study the effectiveness of melphalan followed by peripheral stem cell transplantation in treating patients who have multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma and Plasma Cell Neoplasm | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| filgrastim | Biological | Filgrastim | ALIAS |
| melphalan | Drug | Melphalan | ALIAS |
| peripheral blood stem cell transplantation | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosed active multiple myeloma defined by: * Lytic disease * Anemia * Hypercalcemia * Secondary renal insufficiency * More than 400 mg/24 hours of urinary protein excretion * Symptomatic hyperviscosity * If previously treated, refractory to no more than 1 regimen * Primary amyloidosis without subsequent multiple myeloma allowed * Abnormal renal function allowed if due to primary disease PATIENT CHARACTERISTICS: Age: * Not specified Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * See Disease Characteristics * Creatinine clearance greater than 50 mL/min if no renal impairment Cardiovascular: * No cardiac function that would preclude study * LVEF greater than 45% Pulmonary: * No pulmonary function that would preclude study * FVC greater than 60% predicted * DLCO greater than 50% predicted Other: * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No greater than 18 months of prior alkylator exposure Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified Other * See Disease Characteristics * No more than 3 prior treatment regimens allowed
References
Publications (0)
Data not yet available
No reference posted for this study.